CADTH | Evidence Driven
CADTH | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
N/A Nab-paclitaxel Gastrointestinal cancer Active
Truqap capivasertib HR-positive, HER2-negative locally advanced or metastatic breast cancer Active
Treanda (in combination with rituximab) Bendamustine hydrochloride Chronic Lymphocytic Leukemia Withdrawn
Prevymis letermovir Cytomegalovirus infection (CMV), prophylaxis Active
TBC lebrikizumab atopic dermatitis Active
Opdivo nivolumab Stage IIB or IIC melanoma, adjuvant Active
Epkinly epcoritamab Relapsed or refractory diffuse large B-cell lymphoma Active
Orgovyx relugolix Advanced prostate cancer Active
Repatha evolocumab Primary hyperlipidemia Active
Keytruda pembrolizumab Gastric or gastroesophageal junction adenocarcinoma Active
Last Updated : April 23, 2024